Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Mutation Number Predicts Outcome in Juvenile Myelomonocytic Leukemia

DOI: 10.1158/2159-8290.CD-RW2015-198 Published December 2015
  • Article
  • Figures & Data
  • Info & Metrics
Loading
  • Major finding: An increase in somatic mutations predicts poorer outcome in juvenile myelomonocytic leukemia (JMML).

  • Concept: Concomitant RAS and PRC2 pathway mutations were identified that drive JMML pathogenesis.

  • Impact: Identification of JMML mutations will allow for patient risk stratification to better guide treatment.

Figure1

Juvenile myelomonocytic leukemia (JMML) is a rare early childhood myeloproliferative neoplasm initiated by somatic or germline RAS-activating mutations. It has a poor prognosis, and hematopoietic stem cell transplantation (HSCT) is the only curative therapy; however, some patients exhibit highly aggressive JMML and relapse after treatment, underscoring the need for methods to stratify patients based on risk to guide treatment decisions. Stieglitz, Taylor-Weiner, and colleagues used whole-exome and targeted deep sequencing to genomically characterize a total of 100 samples from patients with JMML, including several matched diagnosis and relapse samples. This analysis confirmed previously reported mutations of RAS pathway genes, and identified other RAS pathway mutations, as well as additional mutations in genes involved in JAK–STAT signal transduction, gene transcription, and splicing. Patients with one or fewer somatic mutations at diagnosis had better outcomes than patients with two or more alterations, and the incidence of relapse in patients treated with HSCT was higher in patients with two or more mutations. Consistent with these findings, Caye and colleagues independently confirmed that additional mutations predict a poor outcome, and identified secondary somatic mutations in sporadic and NF1-associated JMML, including gain-of-function mutations in RAC2. Surprisingly, in both studies, a subset of patients was found to have coexisting RAS pathway mutations, which had largely been considered mutually exclusive and were associated with decreased event-free survival. Furthermore, both groups identified mutations in components of the epigenetic regulator polycomb repressive complex 2 (PRC2), which were shown by Caye and colleagues to decrease PRC2 dosage and alter histone H3 modifications. Taken together, these findings indicate that a dose-dependent, cooperative effect of RAS-activating mutations is important in JMML, but that other mutations have major effects on JMML severity, relapse, and survival. This information has prognostic importance in determining patient risk and identifies mutations that should be further investigated for potential targeted JMML therapies.

Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet 2015 Oct 12 [Epub ahead of print].

Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet 2015 Oct 12 [Epub ahead of print].

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutation Number Predicts Outcome in Juvenile Myelomonocytic Leukemia
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mutation Number Predicts Outcome in Juvenile Myelomonocytic Leukemia
Cancer Discov December 1 2015 (5) (12) OF11; DOI: 10.1158/2159-8290.CD-RW2015-198

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mutation Number Predicts Outcome in Juvenile Myelomonocytic Leukemia
Cancer Discov December 1 2015 (5) (12) OF11; DOI: 10.1158/2159-8290.CD-RW2015-198
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Figures & Data
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • T-cell Receptor–Engineered T Cells Show Efficacy in HPV+ Carcinomas
  • Germline Genetic Variation Modulates Tumor Immune Microenvironment
  • Computational Analysis Finds Protein Stability–Related Cancer Mutations
Show more Research Watch

Genomics

  • Hürthle Cell Carcinomas Exhibit Widespread Loss of Heterozygosity
  • Paralog Dependency May Be Exploitable in Tumors Lacking Chromosome 1p
  • Error-Prone DNA Repair Targets the H3K36me3 Chromatin of Active Genes
Show more Genomics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement